Menu Search
Equities

Zai Lab Ltd

ZLAB:NMQ

Zai Lab Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.70
  • Today's Change-0.530 / -2.02%
  • Shares traded2.70m
  • 1 Year change-6.27%
  • Beta0.9790
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Zai Lab Ltd grew revenues 24.03% from 215.04m to 266.72m while net income improved from a loss of 443.29m to a smaller loss of 334.62m.
Gross margin63.37%
Net profit margin-76.13%
Operating margin-95.07%
Return on assets-26.70%
Return on equity-34.98%
Return on investment-33.48%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Zai Lab Ltd fell by 218.01m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 198.18m for operations while cash used for investing totalled 10.78m.
Cash flow per share-2.66
Price/Cash flow per share--
Book value per share6.78
Tangible book value per share6.23
More ▼

Balance sheet in USDView more

Zai Lab Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.28% of the market capitalization can be attributed to its 790.15m and debt could be paid in full if management chose.
Current ratio3.01
Quick ratio2.87
Total debt/total equity0.1692
Total debt/total capital0.1447
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.